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The androgen receptor (AR) is required for prostate cancer
developmentandcontributes to tumorprogressionafter remission
in response to androgen deprivation therapy. Epidermal growth
factor (EGF) increases AR transcriptional activity at low levels of
androgen in theCWR-R1prostate cancer cell linederived fromthe
castration-recurrent CWR22 prostate cancer xenograft. Here we
report that knockdown of AR decreases EGF stimulation of pros-
tate cancer cell growth and demonstrate a mechanistic link
between EGF and AR signaling. The EGF-induced increase in AR
transcriptional activity is dependent on phosphorylation at mito-
gen-activated protein kinase consensus site Ser-515 in the AR
NH2-terminal region and at protein kinase C consensus site Ser-
578 in theARDNAbindingdomain.Phosphorylationat these sites
alters the nuclear-cytoplasmic shuttling of AR and AR interaction
with theKu-70/80 regulatory subunits ofDNA-dependent protein
kinase. AbolishingAR Ser-578 phosphorylation by introducing an
S578A mutation eliminates the AR transcriptional response to
EGFandincreasesbothARbindingofKu-70/80andnuclear reten-
tion of AR in association with hyperphosphorylation of AR Ser-
515.Theresults supportamodel inwhichARtranscriptionalactiv-
ity increases castration-recurrent prostate cancer cell growth in
response to EGF by site-specific serine phosphorylation that regu-
lates nuclear-cytoplasmic shuttling through interactions with the
Ku-70/80 regulatory complex.
The androgen receptor (AR)3 is required for normal prostate
development and the onset and progression of prostate cancer.
AR has a modular structure characteristic of steroid hormone
receptors, with an NH2-terminal transcriptional activation
domain, DNA binding domain, hinge region, and carboxyl-ter-
minal ligand binding domain (1, 2). AR mediates the biological
effects of androgens by binding testosterone and dihydrotest-
osterone (DHT) with high affinity (3). Androgen binding in the
ligand binding domain stabilizes AR through theNH2- and car-
boxyl-terminal N/C interaction that increases AR transcrip-
tional activity (4). Androgen deprivation by surgical or chemi-
cal castration to treat advanced prostate cancer reduces AR
transcriptional activity and promotes tumor regression.
Several mechanisms have been proposed to explain the
emergence of castration-recurrent prostate cancer during
androgen deprivation therapy (for review, see Ref. 5). AR tran-
scriptional activity and CWR-R1 human prostate cancer cell
proliferation are hypersensitive to DHT (6). AR localizes in the
nuclei of prostate cancer cells despite low levels of circulating
androgen and appears tomediate recurrent growth after andro-
gen deprivation (7). This could be explained by the presence of
sufficient testosterone or DHT to activate AR in the microen-
vironment of castration-recurrent prostate cancer tissue (8, 9).
On the other hand, cell culture studies suggest that AR tran-
scriptional activity involves growth factor signaling under con-
ditions of androgen deprivation.
HER2/neu, keratinocyte growth factor, insulin-like growth
factor-1, and interleukin-6 have been reported to activate AR in
the absence of androgen (10–12). Epidermal growth factor
(EGF)-dependent phosphorylation of transcriptional intermedi-
ary factor 2 and heregulin signaling through the HER2 and
HER3 tyrosine kinases increaseAR transactivation and alter the
growth of CWR-R1 prostate cancer cells in response to low
levels of androgen (13). HER2 and HER3 activation, possibly
through autocrine signaling, contributes to cell proliferation
during prostate cancer recurrence. Growth factor signaling
contributes to the onset of castration-recurrent prostate cancer
through cross-talk between AR and autocrine loops that drive
prostate cancer growth in the androgen-deprived patient.
Despite evidence for AR transcriptional activity in castra-
tion-recurrent prostate cancer, there is little consensus regard-
ing the mechanisms involved in growth factor-mediated AR
phosphorylation (14). The present study determined the effects
of EGF on AR phosphorylation, nuclear localization, gene
transactivation, and prostate cancer cell proliferation.Wedem-
onstrate that AR is required for CWR-R1 prostate cancer cell
growth in response to androgen or EGF and that DHT and EGF
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act synergistically to increase cell growth. EGF-dependent
phosphorylation at MAP kinase consensus site Ser-515 in the
AR NH2-terminal domain and protein kinase C consensus site
Ser-578 in the AR DNA binding domain regulate AR nuclear-
cytoplasmic shuttling through interactions with the Ku-70/80
regulatory subunits of DNA-dependent protein kinase (DNA-
PK). The studies suggest that AR phosphorylation in the P-box
of the DNA-binding-domain first zinc module regulates AR
transactivation in response to EGF signaling.
EXPERIMENTAL PROCEDURES
RNA Interference and Transcription Assays—Duplex AR-
siRNA-3 was ucaaggaacucgaucguauuu (sense) and auacgauc-
gaguuccuugauu (antisense) sequences, and AR-siRNA-4 was
gaaaugauugcacuauugauu (sense) and ucaauagugcaaucauuucuu
(antisense) sequences (NCBI M20132) (SMART selection
designed siRNAs, Dharmacon Inc., Lafayette, CO). The control
was siCONTROL nontargeting siRNA pool (Dharmacon Inc.).
CWR-R1 prostate cancer cells derived from theCWR22 castra-
tion-recurrent prostate cancer xenograft (6, 15) were trans-
fected using Effectene (Qiagen, Valencia, CA) with 10 nM AR
siRNA or control siRNAduplex and 0.1g ofmousemammary
tumor virus luciferase reporter (MMTV-Luc). CWR-R1 cells
were plated (1.6  105 cells/well) in 12-well plates using Rich-
ter’s improved minimal essential prostate growth medium
(Irvine Scientific, Santa Ana, CA) or Dulbecco’s modified
Eagle’s medium (DMEM, Invitrogen), each supplemented with
10 nM nicotinamide, 5 g/ml insulin, 5 g/ml transferrin, 5
ng/ml selenium, 100 units/ml penicillin, 100 g/ml streptomy-
cin, and 2% fetal bovine serum (FBS). DMEM growth medium
was further supplemented with 15 mM HEPES, pH 7.2. DNA
and siRNA (220l) containing per well 45l of EC buffer (Qia-
gen), 1 l of enhancer, 1 l of Effectene reagent (Qiagen), and
200 l of 2% serum-containing medium was added to cell cul-
tures containing 0.8 ml of fresh medium. The next day the
medium was replaced with phenol red-free, serum-free
ImprovedMinimal Essential ZincOptionmedium (Invitrogen)
with and without DHT, and EGF and incubations were contin-
ued for 24 h. For protein kinase C (PKC) inhibition studies cells
were treated with and without calphostin (Calbiochem), a PKC
inhibitor, 1 h before transfection. Cells were treated again the
next day in serum-free medium with and without calphostin in
the absence and presence of 10 ng/ml EGF. Human endome-
trial Ishikawa cells were transfected using FuGENE-6 (Roche
Applied Science) as previously described (16) with 0.025 g of
pCMV-AR and 0.1 l of PSA-Enh-Luc. Cells were harvested in
0.25ml of lysis buffer containing 1%TritonX-100, 2mMEDTA,
and 25 mM Tris phosphate, pH 7.8 (17). Luciferase activity was
measured using an automated LumiStar Galaxymultiwell plate
reader luminometer (BMG Labtechnologies, Durham, NC).
Transfection data are representative of at least three independ-
ent experiments.
Construction of Self-complementary Adeno-associated Virus
(scAAV)-AR-siRNA and scAAV-control (CTR)-siRNA—
pSilencer 1.0-U6 siRNAcontaining anRNApolymerase III pro-
moter (18, 19) (Ambion Inc., Austin, TX) and the Insert Design
Tool for the pSilencer Vectors (Ambion) were used to generate
hairpin siRNAencodingDNAoligonucleotide sequences based
on the siRNA-3 sequence. A central loop sequence ttcaagaga
and single overhang strand were added for cloning. Oligonu-
cleotides that target AR were aaggaactcgatcgtatcattcaagagatgat-
acgatcgagttccttgatttttt (sense, 55 nucleotides) and aattaaaaaatcaa-
ggaactcgatcgtatcatctcttgaatgatacgatcgagttccttggcc (antisense, 63
nucleotides) with 5-EcoRI and 3-ApaI terminal restriction
sites. Control scAAV duplex oligonucleotides were ttctccgaac-
gtgtcacgtttcaagagaacgtgacacgttcggagaatttttt (sense, 53 nucleo-
tides) and aattaaaaaattctccgaacgtgtcacgttctcttgaaacgtgacacgtt-
cgagaaggcc (antisense, 61 nucleotides). Oligonucleotides were
annealed by incubating at 90 °C for 3 min in the presence of 46
l of annealing buffer containing 0.1 M potassium acetate, 2mM
sodium acetate, and 0.03 M HEPES-KOH, pH 7.4, followed by
1 h of incubation at 37 °C. pSilencer 1.0-U6 was linearized with
ApaI and EcoRI and ligated overnight at 25 °C to the siRNA
insert. Type II scAAVexpression vectors ptrs-U1a-RFP-U6 and
ptrs-U1a-green fluorescent protein and helper plasmids pXX6
(adenoviral helper genes) and pXX2 (AAV helper genes) were
generously provided byDouglasM.McCarthy and JudeR. Sam-
ulski (Gene Therapy Center, University of North Carolina at
Chapel Hill). p-trs-U1a-RFP-U6 contains a small nuclear RNA
U1a promoter to drive expression of red fluorescent protein
derived from pDSRED2-C1 (Clontech, Palo Alto, CA). The U6
promoter and duplex sequences were excised from pSilencer
1.0-U6 and cloned into ptrs-U1a-RFP-U6 linearized with NotI
and KpnI. In-frame ligation was confirmed by sequencing.
scAAV vectors produced in human embryonic kidney 293 cells
using three-plasmid transfection were purified as described
(20).
Human embryonic kidney 293 cells (2 107/dish) in DMEM
containing 10% FBS were plated in twenty 15-cm dishes for
70–80% confluency after 24 h. Each plate was passaged 1:4 in
15-cm dishes, and 16 h later the medium was replaced with
complete Iscove’s modified Dulbecco’s medium (Invitrogen)
containing 10% FBS and incubated for 3 h before transfection.
pXX6 helper plasmid (90 g) was combined with 30 g of con-
trol orAR-siRNA-scAAVvector plasmid, 30g of pXX2helper
plasmid, 0.25 M CaCl2, 0.25 M NaCl, 1.5 mM sodium phosphate,
and 0.05 M Hepes, pH 7.2. Cells were incubated for 24 h, and
medium was replaced with DMEM containing 2% FBS. Virus
was collected 48 h post-transfection by lysing cells using 3
freeze-thaw cycles. scAAV vectors were purified by isopycnic
centrifugation in CsCl (  1.4 g/ml) using an SW41 rotor
(Beckman Instruments) at 40,000 rpm for 48 h at 10 °C. Frac-
tions were collected and semiquantitated by slot-blot, and peak
fractions were pooled and dialyzed in phosphate-buffered
saline (PBS) overnight at 4 °C.
To test transduction efficiency of the scAAV serotype II in
CWR-R1 cells, cells were infectedwith scAAV type II ptrs-U1a-
green fluorescent protein virus in medium containing 2% FBS.
Cells were harvested 1 and 9 days post-infection. Green fluo-
rescent protein expression in transduced cells was analyzed by
fluorescence-activated cell sorting using a FACScan1 cytome-
ter (BDBiosciences). Forward and side scatter parameters were
set according to cell size, and the setting for fluorochrome
detection was adjusted so that fluorescence intensity of unin-
fected negative control cells was within the first decade of the
four-scale log plot.
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Cell Proliferation Assays—CWR-R1 prostate cancer cells
(1.6  105/well) in 12-well plates were allowed to grow in pros-
tate growth medium for 24 h. Cells were infected with 103 viral
particles/cell inmedium containing 2% FBS by rocking for 30min
at room temperature and incubated overnight at 37 °C in serum-
containingmedium.Cellswere transferred to serum-free, phenol-
red-free medium in the absence and presence of DHT and EGF.
Duplicate wells were treated and assayed on days 1, 3, and 5
after infection. One-tenth volume of 2-(2-methoxy-4-nitro-
phenyl)-3-(4-nitrophenyl)-5-(2,4-disulfo-phenyl)-2H-tetra-
zolium monosodium salt (WST-8, Dojindo Molecular Tech-
nologies, Gaithersburg, MD) was added to the wells and
incubated for 2.5 h at 37 °C, and absorbance was determined at
450 nmusing a plate reader. The effect of inhibiting PKCon cell
proliferation was assayed using cells plated inmedium contain-
ing 2% FBS. The next day cells were treated with calphostin
(Calbiochem), a PKC inhibitor, in the absence and presence of
EGF. Proliferation assays were performed 1, 3, 5, and 7 days
after treatment.
Plasmids—Expression vectors pCMVhAR for full-length
humanAR (21), pCMVhAR-(1–660) for the ARNH2-terminal,
DNA binding and hinge regions, and AR-(507–660) for part of
theARNH2-terminal domain,DNAbinding domain, andhinge
region were described (1, 22). Mutations in pCMVhAR were
generated by PCR amplification and verified by sequencing.
FLAG-AR-(507–660) was created by subcloning pCMVhAR
mutants into EcoRI- and SalI-digested pCMV-FLAGb. Gluta-
thione S-transferase (GST) fusion vector GST-AR-(1–660) was
prepared as described (23). GST-AR-(1–660)-S578A was gen-
erated by site-directed mutagenesis using the QuikChange kit
(Stratagene) and confirmed by sequencing. Prostate-specific
antigen enhancer luciferase reporter vector (PSA-Enh-Luc)
was provided by Michael Carey (University of California, Los
Angeles) and contains the PSA upstream enhancer region (24).
MMTV-Luc was provided by Stanley M. Hollenberg and Ron
M. Evans (Salk Institute).
Immunochemistry—AR phospho-Ser-578 antipeptide anti-
body was raised in rabbits (21st Century Bio,Marlboro,MA) by
immunizing with two bovine serum albumin-coupled peptides
that were based on human AR sequence 572GALTCGSCKVF-
FKRA586. Peptide 1 was acetyl-Gly-Ser(P)-aminobutyrate-KV-




mino-butyrate-KVFFKRA-amide was used to establish binding
specificity. Aminobutyrate replaced cysteine to avoid disulfide
bonding, aminohexanoic acid was a six-carbon spacer, and the
carboxyl-terminal cysteine was coupled to bovine serum
albumin.
Immunoblotting was performed using monkey kidney
COS-1 cells maintained in DMEM containing 2 mM L-gluta-
mine, 10% bovine calf serum, penicillin, streptomycin, and 20
mM Hepes, pH 7.2. COS cells (2.5  106/10-cm dish) were
transfected with 2 g of DNA using DEAE-dextran (25). Cells
were treated 24 h after transfection with and without 10 ng/ml
EGF for 5 h. For MAP kinase inhibition studies, cells were
treated for 1 h before transfection with and without U0126
(Promega). The next day cells were serum-starved in the
absence and presence of U0126, and media were replaced 24 h
later with and without 10 ng/ml EGF for 5 h. Cells were rinsed
with PBS, scraped into 1.5 ml of cold PBS, and centrifuged at
12,000  g for 2 min. The buffer was aspirated, and cells were
resuspended and vortexed for 10 s in 50–100-l buffer contain-
ing 1% Nonidet P-40, 0.15 M NaCl, 1% sodium deoxycholate,
0.1% SDS, 0.5 mM EDTA, 50 mM Tris-HCl, pH 7.5, 0.02 mg/ml
pancreas extract, 1 mM phenylmethylsulfonyl fluoride, 0.005
mg/ml Pronase, 0.0005 mg/ml thermolysin, 0.003 mg/ml chy-
motrypsin, and 0.33 mg/ml papain (Roche Applied Science).
After a 15-min incubation on ice, lysates were centrifuged for
15 min at 20,000  g, and protein concentrations were deter-
mined using the Bio-Rad assay. Protein (25 g) was incubated
with and without 2.5 units -phosphatase (Sigma) in phospha-
tase buffer (Sigma) containing 2mMMnCl2. To inhibit -phos-
phatase activity, lysates were incubated with 2.5 mM sodium
vanadate, 10 mM sodium fluoride, and phosphatase Mixture
Inhibitors 1/2 (Sigma) for 30 min at 25 °C.
To express FLAG-tagged constructs inCWR-R1 cells, 3g of
DNA/5  106 cells/10-cm dish was transfected using Effectene
(Qiagen). The next day CWR-R1 cells were treated with and
without 10 ng/ml EGF for 5 h, harvested in cold PBS from 5
pooled dishes for each treatment group, and lysed in immuno-
precipitation buffer containing 0.5% Nonidet P-40, 10% glyc-
erol, 0.05 M sodium fluoride, 0.15 M NaCl, 50 mM Tris-HCl, pH
7.6, and phosphatase and protease inhibitors. For immunopre-
cipitation of full-lengthAR expressed inCOS cells, 0.5MDHT
was added to the lysis buffer. Approximately 1 mg of protein
from two 10-cm COS cell dishes was precleared using Sepha-
rose CL-4B (Sigma) and immunoprecipitated using anti-FLAG
M2 affinity resin (Sigma). The final pellets were washed 3 times
with immunoprecipitation buffer with and without 0.5 M
DHT and resuspended in 60 l of 2 sample buffer containing
3.3% SDS, 10% glycerol, 0.2% 2-mercaptoethanol, and 20 mM
Tris-HCl, pH 6.8, and analyzed by immunoblot.
For immunoblots of cell extracts, 4% total protein was sepa-
rated on 10% acrylamide gels containing SDS. After electro-
phoresis, gel proteins were electroblotted to Immobilon-P
membrane (Millipore Corp., Bedford, MA) overnight. Transfer
blots were blocked overnight at 4 °C in 5% milk, 0.9% NaCl,
0.05% Tween 20, and 0.01 M Tris-HCl, pH 7.5. Blots were incu-
bated for 1–2 hwith 2.5g/ml rabbit polyclonal AR52 antibody
targeting human AR NH2-terminal amino acid residues 544–
558 (21), anti-FLAGM2monoclonal antibody (1:2000 dilution,
F-3165 Sigma), -actin antibody AC-15 (1:5000 dilution,
Abcam, Inc.), or Ku (p70) and Ku (p80) antibodies (0.5 g/ml,
MS-329 and MS-285, Lab Vision Corp., Fremont, CA). Anti-
rabbit or anti-mouse horseradish peroxidase-conjugated sec-
ondary IgG antibodies (1:10,000 dilution, Amersham Bio-
sciences) were incubated for 30 min at room temperature.
Signals were detected using chemiluminescence (SuperSignal
West Dura Extended Duration Substrate, Pierce).
Reactivity of AR phospho-Ser-578 antisera was determined
by immunoblot of bovine serum albumin (BSA), BSA-coupled
AR-(572–586) non-phosphorylated peptide and AR-(572–586)
phospho-Ser-578 peptides 1 and 2 immunogens, and wild-type
FLAG-AR-(507–660) and the S578A mutant. COS cells (2.5 
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106/10-cmdish) were transfectedwith 2g of wild-type FLAG-
AR-(507–660) and the S578Amutant, and 24 h later cells were
placed in serum-free, phenol-red free media for 24 h and
treated with and without 10 ng/ml EGF for 5 h. Cells were lysed
in immunoprecipitation buffer containing phosphatase and
protease inhibitors, immunoprecipitated using anti-FLAG M2
affinity resin (Sigma), and resolved on a 12% acrylamide gel
containing SDS. Transfer blots were probed with AR phospho-
Ser-578 antisera (1:100 dilution) and 2.5 g/ml AR52 antibody
at room temperature for 2 h and with secondary antibody as
described above. After chemiluminescence detection, mem-
branes were rinsed with distilled water and incubated for 10
min at room temperature with 0.2% Ponceau S in 0.1% glacial
acetic acid.
Immunocytochemistry was performed in COS cells (1  105
cells/well) in 12-well plates with a coverglass (26). Cells were
transfected using Effectene with 0.2 g of wild-type FLAG-AR-
(507–660) or the S578A mutant and serum-starved 24 h. Cells
were fixed for 10 min at room temperature with 4% paraform-
aldehyde in PBS, permeabilized for 5 min at 4 °C with 0.2%
Triton-X-100 in PBS, blocked for 1 h at room temperature with
0.5%bovine serumalbumin in PBS (13), and incubated for 1 h in
0.5% bovine serum albumin containing AR52 antibody (2.5
g/ml) and for 30 min at room temperature with fluorescein
isothiocyanate-conjugated anti-rabbit secondary antibody
(1:75 dilution, Jackson ImmunoResearch Laboratories, Inc.).
Slides were viewed using an Olympus BX60 microscope with
original magnification of 40.
In Vitro Kinase Assays—GST-AR-(1–660) and GST-AR-(1–
660)-S578A were expressed in BL21 Escherichia coli cells
treated with 1mM isopropyl--thiogalactoside for 24 h at 16 °C
during log phase growth. Glutathione-agarose beads (Amer-
shamBiosciences) were incubated for 1 h at 4 °Cwith sonicated
bacterial supernatants containing GST-AR fusion proteins.
Beads were washed 3 times with PBS containing 1% Triton-X-
100 followed by 3 washes with kinase buffer containing 10 mM
EGTA, 0.1 M MgCl2, and 0.4 M Mes, pH 6.0. Part of the sample
eluted with sample buffer was analyzed on 8–12% acrylamide
gradient gels containing SDS. A serial dilution of bovine serum
albumin was analyzed in parallel to estimate protein recovery.
Bound protein (10–15 g) was assayed for PKC phosphoryla-
tion. GST beads were resuspended in 30 l of kinase buffer
containing 10 or 100 Ci of [-32P]adenosine triphosphate
(3000 Ci/mmol) and 20 ng of purified PKC (catalytic subunit,
rat brain, Calbiochem) in the absence and presence of 1 M
unlabeled adenosine triphosphate and either 2.5 g of calf thy-
mus histone H1 (Calbiochem) or 2.5 g of wild-type or mutant
GST-AR-(1–660) fusion protein. After 10 min at 30 °C, reac-
tion products were resolved on 8–12% acrylamide gradient gels
containing SDS, which were dried and analyzed by autoradiog-
raphy. To verify equal loading, gels were rehydrated in PBS and
stained with Coomassie Blue, or half of the input resin was
resuspended in 2 SDS sample buffer and analyzed by immu-
noblotting using AR52 antibody. Autoradiographs were quan-
titated by densitometric scanning using Image-Pro Analyzer
Software (Media Cybernetics, Inc., Bethesda, MD).
Nuclear Extraction—FLAG-AR fusion vectors were trans-
fected into COS cells (2.5  106/10-cm dish) using DEAE dex-
tran. The next day cells were serum-starved and 24 h later
treated with 10 ng/ml EGF for 5 h. Nuclear extracts were pre-
pared using the Nuclear Extract kit (Active Motif, Carlsbad,
CA). Cells were washed with ice-cold PBS containing phospha-
tase inhibitors, scraped, and pelleted for 5 min at 2600  g,
resuspended in 550l of hypotonic buffer, and incubated for 15
min on ice. Detergent (25 l) was added, and samples were
vortexed for 10 s at the highest setting. Cell suspensions were
centrifuged for 30 s at 14,000  g, and cytoplasmic extracts
were stored at80 °C. Nuclear cell pellets were resuspended in
50 l of complete lysis buffer containing 1 mM dithiothreitol
and protease inhibitor mixture. Lysates were vortexed for 10 s,
and suspensions were incubated for 30 min on ice on a rocking
platform at 4 °C. Extracts were vortexed 30 s and centrifuged 10
min at 14,000  g, and nuclear fractions were transferred to
pre-chilled microcentrifuge tubes. Protein concentration was
determined, and nuclear and cytoplasmic extracts were ana-
lyzed by immunoblotting using 2.5 g/ml AR52, tubulin- (2
g/ml, Thermo Fisher Scientific, Fremont, CA) and Laminin
B1 antibodies (2 g/ml, Active Motif).
RESULTS
AR-dependent CWR-R1 Prostate Cancer Cell Proliferation—
We investigated the requirement for AR in castration-recur-
rent prostate cancer cell growth using the CWR-R1 cell line
that was derived from the castration-recurrent CWR22
xenograft of human prostate cancer (6). Growth studies were
performed using CWR-R1 cells infected with control or AR-
targeted siRNA-scAAV in the absence and presence of DHT
and/or EGF. AR-siRNA-scAAV-infected cells grew more
slowly than control cells in the absence and presence of 0.1 nM
DHT (Fig. 1A). The 90% reduction in AR levels in CWR-R1
cells treated with and without DHT, assayed by immunoblot 2
and 5 days after AR-siRNA-scAAV infection (Fig. 1B), sug-
gested that CWR-R1 cell growth was stimulated by AR both in
the absence and presence of androgen.
EGF also stimulated control CWR-R1 cells to grow faster
than cells infected with AR-siRNA-scAAV (Fig. 2A, left panel).
FIGURE 1. Inhibition of CWR-R1 cell growth by AR-siRNA-scAAV in the
absence and presence of DHT. A, CWR-R1 cells were infected with control or
AR-targeted siRNA-scAAV (103 virus particles/cell) and cultured with or with-
out 0.1 nM DHT. Colorimetric assays at 450 nm using WST-8 reagent were
performed in duplicate to measure cell proliferation daily up to 5 days.
Medium was replaced every other day with or without 0.1 nM DHT as indi-
cated. B, immunoblots of endogenous AR in CWR-R1 cells were performed 2
and 5 days after infecting cells with control siRNA scAAV (CTR) or AR-siRNA-
scAAV in the absence (top panels) and presence of 0.1 nM DHT (bottom panels).
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The reduction in AR levels determined by immunoblot of EGF-
treated CWR-R1 cells 2 and 5 days after AR-siRNA-scAAV
infection (Fig. 2A, right panels) provided evidence that EGF
stimulation of CWR-R1 cell growth was mediated in part by
AR.However, the attenuated but significant growth response of
AR-siRNA-scAAV-infected cells to EGF suggested that EGF
also stimulated cell proliferation through signaling mecha-
nisms that were independent of AR. The stimulatory effect of
EGF together with DHT on growth of control and AR-siRNA-
scAAV-infected cells was greater than DHT or EGF alone and
approached maximal levels within 3 days (Fig. 2B, left panel).
Growth of AR-siRNA-scAAV-infected cells treated with DHT
and EGF was less attenuated compared with control cells even
though AR levels were reduced as shown by immunoblot (Fig.
2B, right panels). The results indicate that AR increases
CWR-R1 prostate cancer cell growth in response to DHT or
EGF and that EGF and DHT act synergistically through AR.
Androgen-independent AR Transactivation—To pursue evi-
dence that AR functions in castration-recurrent prostate can-
cer in the absence of androgen, we tested whether EGF can
increase endogenous AR transcriptional activity in CWR-R1
cells using an MMTV-Luc reporter vector in the absence and
presence of DHT. As expected, DHT increased AR transcrip-
tional activity100-fold, with a further 3-fold increase after the
addition of EGF (Fig. 3A). A similar effect of DHT with and
without EGF on AR transcriptional activity was seen after
transfection of a control siRNA oligonucleotide that did not
reduce AR levels (Figs. 3, A and B, lane 5). However, AR-tar-
geted siRNA oligonucleotide-3 that reduced AR levels (Fig. 3B,
lane 3) greatly reduced AR transactivation, with only a 2-fold
increase in activity remaining in the presence of DHT and an
12-fold increase in response to DHT and EGF (Fig. 3A). In
response to EGF alone, the 3-fold increase in AR transcrip-
tional activity in the presence of control siRNA was abrogated
by AR duplex siRNA oligonucleotide-3 (Fig. 3C).
The results indicate that EGF can activateAR in theCWR-R1
prostate cancer cell line in the absence of androgen and that
EGF andDHT act synergistically to increase AR transcriptional
activity. These data together with the cell growth studies pre-
FIGURE 2. Inhibition of EGF and EGF plus DHT-stimulated CWR-R1 cell
growth using AR-siRNA-scAAV. A, CWR-R1 cells were infected with control
or AR targeted siRNA-scAAV and cultured with or without 10 ng/ml EGF. Cell
proliferation was assayed in the absence or presence of 10 ng/ml EGF as
described in Fig. 1 (left panel). AR expression was determined by immunoblot-
ting CWR-R1 cell lysates 2 and 5 days after infecting cells with control siRNA-
scAAV or AR-siRNA-scAAV in the presence of EGF (right panels). B, CWR-R1
cells were infected with control or AR targeted siRNA-scAAV and treated with
and without 10 ng/ml EGF and 0.1 nM DHT (left panel). Immunoblots of
CWR-R1 cell AR were performed 4 days after infecting cells with control
siRNA-scAAV or AR-siRNA-scAAV in the presence of 10 ng/ml EGF and 0.1 nM
DHT (right panel).
FIGURE 3. Inhibition of DHT and/or EGF stimulated AR transcriptional
activity using AR siRNA. CWR-R1 cells were transfected with 0.1 g of
MMTV-Luc with or without 10 nM AR siRNA-3 or control siRNA (CTR). The next
day cells were cultured for 24 h with or without 0.1 nM DHT in the absence or
presence of 10 ng/ml EGF (A) or in the absence and presence of EGF alone (C),
and luciferase activity was determined. In B, COS cell extracts (30 g of pro-
tein/lane) from cells transfected with pCMV5 empty vector (p5, lane 1) or
pCMV-AR in the absence (lane 2) or presence of 10 nM AR-siRNA-3 (lane 3),
AR-siRNA-4 (lane 4), or control siRNA (lane 5) were analyzed by immunoblot
using AR52 (2.5 g/ml) and -actin antibodies (1:5000 dilution).
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sented above support the hypothesis that AR activation by EGF
is sufficient to drive prostate cancer cell growth.
EGF-dependent AR Phosphorylation—Sequence analysis
using NetPhos 2.0 (27) indicated 15 consensus serine, threo-
nine, or tyrosine phosphorylation sites between AR residues
507 and 660 that comprise part of the ARNH2-terminal region,
theDNAbinding domain, and hinge region (Fig. 4A). Immuno-
blots of wild-type FLAG-AR-(507–660) expressed in COS cells
revealed a 21-kDa protein and, after treatment with EGF, an
additional slower migrating 23-kDa form (Fig. 4B, lanes 1–3).
The EGF-dependent slower migrating form was eliminated by
treatment with -phosphatase in the absence but not in the
presence of phosphatase inhibitors (Fig. 4B, lanes 3–8). The
slowermigrating 23-kDa bandwas also observed in response to
EGF with FLAG-AR-(507–660)-C576A, which has a cysteine
mutation in the first zinc module that eliminates DNA binding
(data not shown). The appearance of an EGF-dependent and
phosphatase-sensitive slower migrating form of FLAG-AR-
(507–660) indicated that EGF induces phosphorylation at one
or more sites between AR residues 507 and 660 independent of
AR binding to DNA.
To identify the EGF-dependent AR phosphorylation site(s),
single serine or threonine to alanine and tyrosine to phenylala-
nine mutations were introduced into FLAG-AR-(507–660) at
the consensus phosphorylation sites highlighted in Fig. 4A.
Immunoblots of cell extracts before and after treatment with
EGF indicated that only theARNH2-terminalMAPkinase con-
sensus S515A mutation eliminated the slower migrating
23-kDa form of FLAG-AR-(507–660) when assayed in COS
and CWR-R1 cells (Fig. 4C, lanes 1–4). This result provided
evidence that AR is phosphorylated at Ser-515 in response to
EGF. In addition, the PKC consensus site mutation S578A in
the AR DNA binding domain increased the relative proportion
of the slower migrating 23-kDa phospho-Ser-515 form in the
presence of EGF (Fig. 4C, lanes 5 and 6). MAP kinase-depend-
ent phosphorylation at AR Ser-515 was supported by the
decrease in intensity of the slower migrating 23-kDa band after
treatment with both EGF and increasing concentrations of the
MAP kinase inhibitor, U0126 (Fig. 4D).
ARphosphorylationatSer-578was indicatedby thereactivityof
an AR phospho-Ser-578-specific antibody that recognized two
AR-(572–586) phospho-Ser-578-conjugated peptides used as
immunogens but not unphosphorylated AR-(572–586) (Fig. 5A,
lanes 3–5).TheARphospho-Ser-578-specific antibody also rec-
ognized the faster migrating 21-kDa form of wild-type
AR-(507–919) but not the S578Amutant (Fig. 5B, upper panel,
lanes 2–5), whereas both forms were detected using the AR52
antibody (Fig. 5B, lower panel). Treatment with -phosphatase
reduced the reactivity of the phospho-Ser-578 antibody reac-
tivity with wild-type AR-(507–919) (data not shown). The
results suggest that the EGF-dependent increase in AR tran-
scriptional activity and CWR-R1 cell growth are associated
withMAP kinase-dependent phosphorylation at AR Ser-515 in
the NH2-terminal region and modulation by phosphorylation
at Ser-578 in the DNA binding domain.
AR Phosphorylation Alters Transcriptional Activity—We
investigated further the link between EGF-dependentARphos-
phorylation and increased AR transcriptional activity using
full-length wild-type AR and serine to alanine mutants
expressed with a PSA-Enh-Luc reporter in CWR-R1 cells. AR
transcriptional activity increased3-fold in response to EGF in
the absence and presence of DHT (Fig. 6A, upper panel). A
similar response was seen with AR-S650A, which has a muta-
tion in the previously reported Ser-650 phosphorylation site in
the hinge region of AR (28, 29). AR-S515A transcriptional
activity increased in response to EGF and DHT, but overall
FIGURE 4. EGF-dependent phosphorylation at AR Ser-515. A, schematic
representation of 15 predicted phosphorylation sites in part of the AR NH2-
terminal region (N-term), DNA binding domain (DBD), and hinge region that
were mutated in FLAG-AR-(507– 660) and tested for band shift on immunob-
lots. B, COS cells were transfected with 2 g of FLAG-AR-(507– 660), serum-
depleted for 24 h, and treated for 5 h with and without 10 ng/ml EGF as
indicated. Cells were harvested, and lysates were incubated with and without
2.5 units of -phosphatase for 30 min at 30 °C in the absence (lanes 1– 4) and
presence of phosphatase inhibitors (lanes 5– 8). C, COS cells (upper panel) and
CWR-R1 cells (lower panel) were transfected with 2 g of wild-type (wt) FLAG-
AR-(507– 660) or the S515A and S578A mutants. Cells were serum-depleted
for 24 h, treated with and without 10 ng/ml EGF for 5 h, collected, and lysed in
the presence of phosphatase inhibitors for immunoprecipitation using FLAG
affinity resin. AR52 antibody was used to detect wt and mutant FLAG-AR-
(507– 660) and an associated slower migrating band indicative of phospho-
rylation. Also indicated is the nonspecific IgG band. D, reduced AR Ser-515
phosphorylation by mitogen-activated protein kinase inhibitor, U0126. COS
cells were treated in the absence (lanes 1–2) and presence of increasing con-
centrations of U0126 (lanes 3– 8) for 1 h before transfection with 2 g of
FLAG-AR-(507– 660). The next day cells were serum-starved for 24 h in the
absence and presence of U0126. Cells were treated again for 5 h with and
without U0126 in the absence (lanes 1, 3, 5, and 7) and presence of 10 ng/ml
EGF (lanes 2, 4, 6, and 8). FLAG-AR-(507– 660) was detected using AR52 anti-
body, and -actin served as the loading control.
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activity was less than wild type. In contrast, EGF did not
increase transcriptional activity of AR-S578A in the absence or
presence of DHT or when the S578A mutation was combined
with the S515A or S650A mutation. When assayed by immu-
noblot (Fig. 6A, lower panel), expression of AR-S578A and
AR-S515A was similar to wild-type AR, as was androgen-de-
pendent AR stabilization that results from the ARN/C interac-
tion (4, 23).
The weaker transcriptional activity of the AR-S578A DNA
binding domain mutant did not result from loss of DNA bind-
ing. This was evident fromAR-(1–660)-S578A, a constitutively
active AR NH2-terminal and DNA binding domain fragment
that retained transcriptional activity of wild-type AR-(1–660)
using the PSA-Enh-Luc reporter (Fig. 6B, upper panel). How-
ever, similar to results with full-length AR-S578A (Fig. 6A),
transcriptional activity of AR-(1–660)-S578A was not
increased by EGF when expression levels of AR-(1–660)-
S578A were similar to wild-type AR-(1–660) (Fig. 6B, lower
panel). AR-(1–660)-S578A also constitutively activated the
MMTV-Luc reporter even though full-length AR-S578A was
inactive with this promoter (data not shown).
To further establish a requirement for Ser-578 in the EGF-
dependent increase in AR transcriptional activity, we per-
formed transcription assays in human endometrial cancer Ish-
ikawa cells using the PSA-Enh-Luc reporter. In the presence of
FIGURE 6. AR Ser-578 required for EGF-induced AR transactivation in
CWR-R1 and Ishikawa cells. A, CWR-R1 cells were transiently transfected with
0.1 g of PSA-Enh-Luc and 10 ng wt pCMV-AR and the S578A, S515A, S515A-
S578A, S650A, and S578A-S650A mutants and incubated for 24 h with and with-
out 0.1 nM DHT and 10 ng/ml EGF as indicated, and luciferase activity was deter-
mined (upper panel). COS cells were transfected using DEAE dextran as described
under “Experimental Procedures” with 2 g of pCMV5 empty vector (), wild-
type pCMV-AR (wt), and the S578A and S515A mutants (lower panel). COS cells
were incubated in the absence and presence of 10 nM DHT and 10 ng/ml EGF as
indicated, and immunoblots were performed to confirm similar expression lev-
els. B, CWR-R1 cells were transfected with 0.1 g of PSA-Enh-Luc and 50 ng of
pCMV-AR-(1–660) wt and S578A mutant and incubated for 24 h with and with-
out 10 ng/ml EGF, and luciferase activity was determined (upper panel). Similar
expression levels were determined by transfecting COS cells with 2 g of wt
pCMV-AR-(1–660) and the S578A mutant and incubating cells for 24 h in the
absence and presence of 10 ng/ml EGF (lower panel). C, Ishikawa cells were trans-
fected with 0.1 g of PSA-Enh-Luc and 25 ng of wild-type pCMV-AR (wt) or S578A
mutant and incubated for 24 h with increasing concentrations of DHT with and
without 10 ng/ml EGF as indicated, and luciferase activity was determined.
FIGURE 5. Phosphorylation at AR Ser-578. A, immunoblots without protein
(lane 1), 2.5 g of bovine serum albumin (BSA, lane 2), bovine serum albumin-
coupled nonphosphorylated AR-(572–586) peptide (lane 3), and AR-(572–
586) phospho-Ser-578 peptides-1 and -2 (lanes 4 and 5) were separated on
10% acrylamide gels. Transfer blots were incubated with AR anti-phospho-
Ser-578 antiserum (1:100 dilution) as described under “Experimental Proce-
dures.” Equivalent loading of the conjugated AR peptides was confirmed by
staining the transfer blot with 0.2% Ponceau S (lower panel). B, COS cells were
transfected with 2 g of pSG5 empty vector (, lane 1), wild-type FLAG-AR-
(507– 660) (lanes 2 and 3), and FLAG-AR-(507– 660)-S578A (lanes 4 and 5). The
next day cells were transferred to serum-free medium and 24 h later treated
for 5 h in the absence and presence of 10 ng/ml EGF as indicated. Cell extracts
were immunoprecipitated using FLAG-M2 affinity resin and separated on a
12% acrylamide gel containing SDS, and transfer blots were incubated with
AR anti-phospho-Ser-578 antisera (1:100 dilution, upper panel) and 2.5 g/ml
AR52 antibody (lower panel) as described under “Experimental Procedures”.
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increasing concentrations of DHT, AR-S578A transcriptional
activitywas similar towild-typeAR (Fig. 6C). This differed from
CWR-R1 cells where AR-S578A transcriptional activity was
less than wild-type AR (Fig. 6A). However, in agreement with
results using the CWR-R1 cell line, the EGF-dependent
increase inwild-typeAR transcriptional activity in the presence
of DHTwas diminished by the AR S578Amutation in Ishikawa
cells (Fig. 6C). The results suggest that phosphorylation at AR
Ser-578 is required for the AR transcriptional response to EGF.
Functional Effects of AR Phosphorylation by PKC—Ser-578 is
a predicted consensus phosphorylation site for PKC, a kinase
that acts downstream of EGF signaling (30). We performed in
vitro kinase assays using the PKC catalytic subunit with wild-
typeGST-AR-(1–660) and the S578Amutant. PKC-dependent
phosphorylation of GST-AR-(1–660) was reduced 30–35% by
the S578A mutation when equivalent amounts of protein were
assayed by immunoblot (Fig. 7A,
lanes 1 and 2), where histone H1
served as a PKC substrate control
(Fig. 7A, lane 3). When averaged
over multiple experiments, the
S578A mutation decreased GST-
AR-(1–660) phosphorylation by
50% (Fig. 7B). The EGF-depend-
ent and independent increase in
CWR-R1 cell growth was reduced
by the PKC-specific inhibitor cal-
phostin (Fig. 7C). The results sug-
gestthatEGFsignalingthroughPKC-
dependent phosphorylation of AR
Ser-578 increases AR transcrip-
tional activity and AR-mediated
CWR-R1 cell growth.
AR Ser-578 Phosphorylation Influ-
ences Nuclear-Cytoplasmic Shutt-
ling—The effect of the S578Amutation onAR subcellular local-
ization was investigated using wild-type and mutant FLAG-
AR-(507–660). Immunostaining showed that wild-type FLAG-
AR-(507–660) distributed between the nucleus and cytoplasm
of transfected COS cells, indicative of nuclear-cytoplasmic
shuttling (Fig. 8A, left panel). The phosphomimetic FLAG-AR-
(507–660)-S578D distributed similarly between the nucleus
and cytoplasm (data not shown), whereas immunostaining of
FLAG-AR-(507–660)-S578A was exclusively nuclear (Fig. 8A,
right panel).
AR compartmentalization was also investigated by compar-
ing nuclear and cytoplasmic extracts of cells expressing FLAG-
AR-(507–660) and the S578A mutant before and after treat-
ment with EGF. In agreement with the immunostaining results,
wild-type FLAG-AR-(507–660) was distributed in both the
nuclear and cytoplasmic fractions (Fig. 8B, lanes 2, 3, 7, and 8).
The slowermigrating 23-kDa phospho-Ser-515 formwasmore
prominent in the nuclear fraction in response to EGF. FLAG-
AR-(507–660)-S515A lacked the slower migrating 23-kDa
form (Figs. 4 and 5) and distributed in both nuclear and cyto-
plasmic extracts similar to wild type (data not shown). How-
ever, in agreement with the immunostaining results, FLAG-
AR-(507–660)-S578A was almost entirely nuclear, and the
proportion of the phospho-Ser-515 form was increased (Fig.
8B, lanes 4, 5, 9, and 10). Parallel immunoblotting of nuclear
laminin-B1 and cytoplasmic -tubulin substantiated the sub-
cellular fractionation results. Cell extracts contained similar
amounts of wild-type and mutant FLAG-AR-(507–660) (data
not shown), suggesting that the smaller amount of the S578A
mutant in the cytoplasmic fraction did not result from degra-
dation. The results suggest that phosphorylation at AR Ser-578
limits nuclear phosphorylation at Ser-515 and modulates AR
nuclear-cytoplasmic shuttling.
Phosphorylation at AR Ser-578 Modulates AR Interaction
with Ku-70/80—TheKu-70/80 regulatory subunits of DNA-PK
were shown to interact with the progesterone receptor DNA
binding domain (31), which shares sequence similarity with the
AR DNA binding domain (32). Ku-70/80 subunits were also
implicated in AR transcriptional recycling (33). To address the
FIGURE 7. PKC-mediated phosphorylation at AR Ser-578 and EGF-dependent CWR-R1 cell growth. A, in
vitro kinase assays were performed using GST-AR-(1– 660) (2.5 g, lane 1) and GST-AR-(1– 660)-S578A (2.5 g,
lane 2) expressed in E. coli and purified by adsorption to glutathione beads. Histone H1 served as a PKC sub-
strate control (2.5 g, lane 3). Assays were performed as described under “Experimental Procedures” using the
PKC catalytic subunit in the presence of 10 Ci of [-32P]adenosine triphosphate (upper panel). Parallel immu-
noblots were probed with AR52 antibody (lower panel). Samples were analyzed by autoradiography and band
intensities measured by densitometry. NS designates a nonspecific phosphorylated band. B, data from four
independent experiments described in A were averaged. C, inhibition of CWR-R1 cell proliferation by calphos-
tin. CWR-R1 cells were plated and serum-starved the next day for 24 h and treated as described under “Exper-
imental Procedures” in serum-free media with and without 10 ng/ml EGF alone or with 50 nM calphostin, a PKC
inhibitor (day 0). Media and additives were replenished every other day over 7 days. Cell proliferation indexes
were measured using WST-8 reagent on days 3, 5, and 7 after seeding.
FIGURE 8. Increased nuclear localization of the AR S578A mutant. A, COS
cells were transfected with 0.2 g of wild-type (wt) FLAG-AR-(507– 660) or the
S578A mutant and serum-starved the next day for 24 h. FLAG-AR-(507– 660)
and the S578A mutant are represented by green fluorescence detected using
AR52 antibody and fluorescein isothiocyanate-conjugated secondary anti-rabbit
antibody. Original magnification 40. B, nuclear and cytoplasmic fractions were
prepared as described under “Experimental Procedures” and analyzed by immu-
noblotting using AR52 antibody that recognizes FLAG-AR-(507–660) wt and the
S578A mutant. Laminin-B1 and -tubulin served as nuclear and cytoplasmic
extract controls, respectively.
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influence of Ser-578 phosphorylation on AR interaction with
Ku-70/80, we performed coimmunoprecipitation studies in
COS cells using full-length wild-type FLAG-AR, the S578A
mutant, and endogenous Ku-70/80. We found that Ku-70 and
Ku-80 coimmunoprecipitated with FLAG-AR-S578A but only
weakly with wild-type AR (Fig. 9A, upper two panels).
In similar experiments using FLAG-AR-(507–660), we
found that the S578A mutant interacted with endogenous
Ku-70 and Ku-80 to a greater extent than wild-type FLAG-AR-
(507–660) in both COS (Fig. 9B) and CWR-R1 cells (Fig. 9C).
Also, as seen with full-length FLAG-tagged AR, the interaction
between wild-type FLAG-AR-(507–660) and Ku-70/80
increased in the response to EGF in both cell lines. A DNA
binding mutant, FLAG-AR-(507–919)-C576A, interacted with
Ku-70/80 to a similar extent as wild type (data not shown). The
results suggest that EGF-dependent phosphorylation at AR
Ser-578 modulates phosphorylation at Ser-515 and regulates
AR interaction with Ku-70/80.
DISCUSSION
EGF Regulation of AR Transcriptional Activity—EGF signal-
ing has been indirectly linked to increased AR transcriptional
activity through the post-translational modification of AR
coregulatory proteins. EGF increases phosphorylation of tran-
scriptional intermediary factor 2, an SRC/p160 coactivator (17),
and phosphorylation and multiple monoubiquitinylation of
MAGE-11 of the melanoma antigen gene family (16). These
changes stabilize the coregulator interaction with AR to
increase AR transcriptional activity. In this report we provide
evidence that EGF increases AR transcriptional activity
through the coordinate phosphorylation of serine residues in
the AR NH2-terminal and DNA binding domains.
We have shown that EGF increases CWR-R1 prostate cancer
cell growth in an AR-dependent manner in the absence and
presence of androgen. EGF acts synergistically with DHT to
stimulate AR transcriptional activity and cell growth. EGF-de-
pendent CWR-R1 prostate cancer cell proliferation was great-
est in the presence of AR and DHT and was reduced by an
inhibitor of PKC.One interpretation suggests that AR signaling
in the absence and presence of DHT establishes a basal prolif-
eration rate that is enhanced by EGF through mechanisms that
includeAR but are also independent of AR. EGF-dependentAR
activation in the absence and presence of androgen is mediated
by PKC-dependent phosphorylation at Ser-578 in the ARDNA
binding domain and by MAP kinase-dependent phosphoryla-
tion at Ser-515 in the AR NH2-terminal region. The down-
stream functional effects of AR phosphorylation at these sites
alter AR nuclear-cytoplasmic shuttling through interactions
with Ku-70/80.
EGF-dependent AR Phosphorylation—Earlier mutagenesis
studies demonstratedARphosphorylation at Ser-81 and Ser-94
in the NH2-terminal region and at Ser-650 in the hinge region
between the DNA and ligand binding domains (28). AR Ser-81
was suggested to be a substrate for the HER2-regulated kinase
pathway (34), and AR phosphorylation at Ser-650 was linked to
stress kinase modulation of AR transcriptional activity (29).
However, mutations at these sites have relatively little effect on
AR transcriptional activity (28, 35). Mass spectrometry con-
firmed AR phosphorylation at Ser-81, -94, and -650 and iden-
tified Ser-16, -256, -308, and -424 as phosphorylation sites in
the AR NH2-terminal region (14). AR NH2-terminal Ser-213
was phosphorylated in nonproliferating prostate epithelial cells
(36), and Akt-mediated phosphorylation at AR Ser-213 and
Ser-791 was linked to anti-apoptotic and proliferative effects in
prostate cancer cells (37, 38). However, the synergistic effects of
Akt and AR on neoplastic proliferation of murine prostatic epi-
thelium were independent of phosphorylation at these sites
(39). More recently, prostate cancer growth was linked to Src
and Ack1-mediated phosphorylation of AR tyrosine residues
267 and 363 in the AR NH2-terminal region (40).
Our current studies focused on theARDNAbinding domain
and flanking NH2-terminal and hinge regions and confirmed
that amutation at Ser-650 has relatively little effect onAR tran-
scriptional activity (28, 35). We also found that mutations at
other previously reported phosphorylation sites in the region,
including a recently reported Src-dependent tyrosine phospho-
rylation site Tyr-534 in the AR NH2-terminal region close to
the DNA binding domain (41), did not diminish AR transcrip-
tional activity in CWR-R1 cells in response to DHT with or
without EGF. The relative lack of functional effects of muta-
tions at most of the previously reported AR phosphorylation
FIGURE 9. AR Ser-578 mediates the interaction with Ku-70/80. COS cells
(A and B) and CWR-R1 (C) cells were transfected with 2 g of wild-type (wt),
FLAG-AR, FLAG-AR-(507– 660) and the S578A mutants as indicated. Cells were
serum-starved the next day for 24 h and treated with and without 1 nM DHT
and/or 10 ng/ml EGF for 5 h as indicated. Protein lysates were immunopre-
cipitated (IP) using anti-FLAG resin and analyzed by immunoblotting. AR-52
antibody was used to detect immunoprecipitated FLAG-AR and Ku-70/80-
specific antibodies for coimmunoprecipitated proteins. Protein lysates (4% of
total) were analyzed for endogenous Ku-70/80 (lower panels).
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sites left unanswered the question of the significance of AR
phosphorylation, particularly in prostate cancer cells where
growth factor and mitogen signaling are increased.
Our studies indicate direct effects of EGF signaling on AR
transcriptional activity through Ser-515 in the NH2-terminal
region and Ser-578 in the DNA binding domain. MAP kinase
phosphorylation site Ser-515 is positioned near the DNA bind-
ing domain (Fig. 10A) carboxyl-terminal to activation func-
tion-1 transactivation domain residues 142–337 required for
androgen-dependent AR transcriptional activity (1, 42). AR
Ser-515 is closer to tau-5 residues 360–485 (43), a transcrip-
tional activation region whose activity is apparent in the AR
NH2-terminal and DNA binding domain fragment that lacks
the ligand binding domain (1, 42).
MAPkinase signalingwaspreviously implicated inandrogen-
dependent AR transcriptional activity (13, 17, 44). In vitroMAP
kinase assays suggested phosphorylation of AR-36–643, an AR
NH2-terminal and DNA binding domain fragment, in response
to HER2/neu signaling (11). Although an AR S515A mutation
reduced the signaling effects of HER2/neu, additional evidence
for phosphorylation at this site was not reported. Here we show
that EGF signaling slowed the gel electrophoretic migration of
an AR NH2-terminal-DNA binding domain-hinge region frag-
ment, an effect that was eliminated by treatment with -phos-
phatase. The EGF-dependent increase in AR transcriptional
activity was linked to phosphorylation at Ser-515 and Ser-578.
MAP kinase consensus site mutation S515A reduced AR tran-
scriptional activity slightly but did not eliminate the AR tran-
scriptional response to EGF in the absence and presence of
androgen. Inhibition of Ser-578 phosphorylation by an S578A
mutation increased phosphorylation at Ser-515, which pro-
vided evidence that AR phosphorylation at Ser-515 is linked to
phosphorylation at Ser-578.
Indeed, EGF-dependent phosphorylation at AR Ser-578
appears to be required for EGF stimulation of AR transcrip-
tional activity. Ser-578 is positioned in the first zinc module of
the AR DNA binding domain (Fig. 10B) within the P-box.
Response elementDNAbinding specificity distinguished by the
glucocorticoid receptor (GR) and estrogen receptor is associ-
ated with three P-box residues, GSXXV (45, 46). Human AR
P-box 577GSCKV581 contains Ser-578 and is common to GR
and the progesterone and mineralocorticoid receptors, each of
which recognizes the GGTACANNNTGTTCT (N is any
nucleoside) consensus response element (47–49). P-box
sequence within this subfamily distinguishes TGTTCT half-
site sequence from TGACCT estrogen response element con-
sensus sequence (46). Within the AR receptor subgroup, DNA
response element binding specificity was attributed to residues
in the second zincmodule and the carboxyl-terminal extension
in the hinge region (50, 51).
Crystal structures of the ARDNAbinding domain-androgen
response element DNA complex indicate that human AR Ser-
578 lies within the first -helix that directly contacts the major
groove of the DNA (Fig. 10C) (52). Human AR Ser-578 corre-
sponds to human GR Ser-440. When GR Ser-440 was changed
to glycine to mimic Gly-204 in human ER or to alanine, GR
DNA binding specificity was reduced. Based on these studies,
the AR Ser-578 hydroxyl group is predicted to modulate DNA
binding specificity through a hydrogen bond network extend-
ing to Arg-608 in the second zinc module loop containing AR
D-box 596ASRND600 (Fig. 10B) (53). Unlike the common P-box
sequence shared by AR, GR, progesterone, and mineralocorti-
coid receptors, the AR D-box, thought to be involved in recep-
tor dimerization and half site spacing recognition, differs from
the AGRND D-box common to other members of this sub-
group of steroid receptors (45, 54). AR Arg-608 corresponds to
Arg-470 in human GR, for which a lysine substitution was pre-
dicted to alter DNA binding specificity by changing the hydro-
gen bonding pattern (53). The importance of AR Arg-608,
which contacts the DNA phosphate backbone and is conserved
in the steroid receptor family, is supported by the naturally
occurring R608K mutation that causes partial androgen
insensitivity.
Anaturally occurringARS578Tmutation also causes grade 5
partial androgen insensitivity, where complete androgen insen-
sitivity (grade 6/7) is associated with an external female pheno-
type in a genetic male (55, 56). The S578T mutation demon-
strates the in vivo importance of Ser-578 in AR function. The
partial response of recombinant AR-S578T to elevated andro-
gen levels in a COS cell transcriptional assay (55) indicates
some retention of DNA binding activity. The extent of phos-
phorylation at residue 578 may be diminished by threonine at
this position and phospho-Ser-578 or phospho-Thr-578 might
alter AR interactionwithDNA (Fig. 10C) or associated proteins
FIGURE 10. AR schematic diagrams. A, full-length human AR amino acid
residues 1–919 contain the NH2-terminal domain (NTD) with activation func-
tion-1 (AF1) and Ser-515, DNA binding domain (DBD) with Ser-578, and ligand
binding domain (LBD) with activation domain-2 (AF2). B, AR NH2-terminal and
DNA binding domain residues 514 – 627 showing the two zinc modules with
highlighted AR phosphorylation sites Ser-515 and Ser-578. C, structure of the
AR DNA binding domain dimer (green) bound to androgen response element
DNA (orange and blue) (52) with space-filled Ser-578 indicated with red
arrows.
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such as Ku-70/80. Rapid release and rebinding of steroid recep-
tors to DNA in a dynamic hit-and-run model has revealed the
transient nature of steroid receptor DNA binding required for
activation of transcription (57, 58). Similar transient interac-
tions were reported for AR binding to androgen response ele-
ment DNA (59). EGF-dependent phosphorylation at AR Ser-
578 may regulate AR association and dissociation from DNA
and the magnitude of the transcriptional response.
We have provided evidence for PKC phosphorylation at AR
Ser-578. Our results support previous evidence that phospho-
rylation by PKC in theDNAbinding domainmodulates nuclear
receptor localization. PKC was shown to phosphorylate highly
conserved Ser-78 between the two zinc modules in the DNA
binding domain of hepatocyte nuclear factor-4 and at a corre-
sponding position in retinoic acid receptor-, retinoid X recep-
tor-, and thyroid hormone receptor- (60). Hepatocyte
nuclear factor-4 Ser-78 is conserved through most of the
nuclear receptor superfamily, including Ser-212 in human
estrogen receptor-. However, the corresponding residue in
the AR subgroup of steroid receptors is alanine and is Ala-586
in humanAR. PKCphosphorylation at Ser-78 in theDNAbind-
ing domain of hepatocyte nuclear factor-4 and other nuclear
receptors regulates nuclear localization (60). Hepatocyte
nuclear factor-4-S78A bound DNA, but the S78D phospho-
mimetic did not. The AR phosphomimetic S578D retained
greater transcriptional activity than AR-S578A but less than
wild-type AR (data not shown), and like wild-type AR, the
S578D mutant was distributed in both the cytoplasm and
nucleus. AR-S578D might be expected to bind less Ku-70/80,
which could interfere with the dynamicmodel of steroid recep-
tor binding to DNA.
The results raise the possibility that phosphorylation by PKC
at conserved serine residues in the first zincmodule of theDNA
binding domain regulates DNA binding for the entire nuclear
receptor family. Phosphorylation within the DNA binding
domainmay be a common regulatory mechanism that controls
nuclear-cytoplasmic shuttling and DNA binding required for
differential gene regulation.
AR Nuclear-Cytoplasmic Shuttling and DNA Binding
Specificity—EGF-dependent AR transcriptional activity medi-
ated by PKC-dependent phosphorylation at AR Ser-578 is
linked to AR nuclear-cytoplasmic shuttling. Based on results
with an AR NH2-terminal, DNA binding, and hinge region
fragment, where the S578A mutant was exclusively nuclear,
EGF-dependent AR phosphorylation at Ser-515 and Ser-578
modulates AR nuclear retention. In addition, AR coimmu-
noprecipitates withKu-70/80, aDNAbinding protein complex
that regulates DNA-PK activity and other transcription factors
(61). The greater nuclear retention of AR-(507–660)-S578A
compared with wild type was associated with increased inter-
action with Ku-70/80. PKC-mediated AR phosphorylation at
Ser-578 appears to regulate the AR interaction with Ku-70/80
and modulate AR nuclear-cytoplasmic shuttling and DNA
binding. Our studies are in agreement with previous evidence
that steroid receptor phosphorylation is linked to nuclear-cy-
toplasmic shuttling (62).
In agreement with evidence that AR-S578A interacts to a
greater extent with Ku-70/80, full-length AR-S578A did not
activate MMTV-Luc in Ishikawa cells (data not shown) even
though AR-S578A transcriptional activity was similar to wild
type in Ishikawa cells using the PSA-Enh-Luc reporter, which
lacks a negative response element (NRE) sequence present in
the MMTV promoter-enhancer. Ku-80 represses GR transac-
tivation through high affinity, sequence-specific binding to
double-stranded negative response element 1 at 394 to 381
in the MMTV long terminal repeat (63, 64). Repression of GR
transactivation of the MMTV promoter correlated with
recruitment ofKu-70/80 to negative response element 1 (64, 65,
66).
Loss of AR-S578A transactivation of MMTV-Luc did not
result from inhibition of AR binding to DNA. In the context of
the AR NH2-terminal and DNA binding domain constitutively
active fragment, AR-S578A retains wild-type activity with
MMTV-Luc (data not shown). This is consistent with a previ-
ous study suggesting thatKu-70/80 interacts preferentiallywith
the AR ligand binding domain (33) and provides further evi-
dence that the effect of the S578A mutation is to increase AR
interaction with Ku-70/80. Our studies suggest that a stronger
interaction between AR and Ku-70/80 is associated with loss of
AR activation of MMTV. In addition, the results support the
concept that EGF-dependent phosphorylation at Ser-578mod-
ulates AR transactivation through its interaction with
Ku-70/80.
EGF-dependent phosphorylation sites Ser-515 and Ser-578
in AR differ from the GR DNA-PK phosphorylation site that
was linked to GR association with Ku-70/80. Human GR hinge
regionDNA-PK phosphorylation site Ser-508 implicated inGR
nuclear retention (63, 66, 67) is positioned close to human GR
nuclear targeting residues 479–498 and is displaced in position
by two residues to the corresponding human AR hinge residue
Ser-650 near AR nuclear targeting residues 617–633 (22, 68).
We and others have shown that a mutation at Ser-650 has rel-
atively little effect on AR transcriptional activity (28, 35). How-
ever, humanARhas aDNA-PK consensus phosphorylation site
656TQ657 in the hinge region, and inhibition of DNA-PK was
reported to reduce AR phosphorylation and nuclear export
(69). Given that AR interacts with Ku-70/80, an interaction that
is enhanced by the S578A mutation, and that Ku-70/80 has
additional functions independent of DNA-PK (65), Ku-70/80
may regulate AR independent of DNA-PK. Ku-70/80 is
reported to have DNA helicase activity (70), which may more
directly influence AR transcriptional activity.
AR Function in Castration-recurrent Prostate Cancer—AR is
an important transcriptional activator in castration-recurrent
prostate cancer growth that follows a period of remission in
response to androgen deprivation therapy. The AR gene is
amplified in approximately one-third of prostate cancers (71).
AR somatic gene mutations in prostate cancer can increase AR
transactivation by androgens and other ligands. However,
although AR mutations are relatively common in established
prostate cancer cell lines, they are infrequent in prostate cancer
tissue specimens and cannot account for the high incidence of
castration-recurrent prostate cancer growth after androgen
deprivation therapy. AR somatic mutations in prostate cancer,
such as AR-H874Y in the CWR22 human prostate xenograft
and the derived CWR-R1 prostate cancer cell line used in the
AR Activation by EGF in Recurrent Prostate Cancer
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present study (6, 15), tend to increase AR sensitivity to ligand-
dependent transactivation through more efficient recruitment
of SRC/p160 coactivators by activation domain-2 in the ligand
binding domain (72). In contrast, ligand-independent AR acti-
vationmay be independent of activation domain-2 in the ligand
binding domain (73), mediated instead by growth factor and
mitogen downstream signaling mechanisms (74). This is sup-
ported by the inability of flutamide to inhibit castration-recur-
rent prostate cancer cell growth (75, 76).
Chromatin studies support AR function in cell proliferation
in castration-recurrent prostate cancer in the absence of andro-
gen (77–81). Adeno-associated viral siRNA knockdown of AR
diminished both DHT and EGF-stimulated CWR-R1 prostate
cancer cell growth. However, residual levels of AR in the AR-
siRNA-scAAV-treated cells appear to be sufficient to mediate
prostate cancer cell growth in response to the synergistic effects
of DHT and EGF, a finding relevant to clinical prostate cancer
since androgens are present in castration-recurrent prostate
cancer tissue (8). In addition, EGF was shown to induce site-
specific phosphorylation and monoubiquitinylation of AR
coregulator MAGE-11 required to interact with AR and
increase transcriptional activity in the absence and presence of
androgen (16). Thus, growth factor and mitogen signaling
throughmultiple mechanisms that involve ARmay account for
the relapse of prostate cancer growth.
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